These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2908755)

  • 1. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine.
    McIntyre PB; Rodrigues CA; Lennard-Jones JE; Barrison IG; Walker JG; Baron JH; Thornton PC
    Aliment Pharmacol Ther; 1988 Jun; 2(3):237-43. PubMed ID: 2908755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
    Mansfield JC; Giaffer MH; Cann PA; McKenna D; Thornton PC; Holdsworth CD
    Aliment Pharmacol Ther; 2002 Jan; 16(1):69-77. PubMed ID: 11856080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different therapy for different types of ulcerative colitis in China.
    Jiang XL; Cui HF
    World J Gastroenterol; 2004 May; 10(10):1513-20. PubMed ID: 15133864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
    Green JR; Gibson JA; Kerr GD; Swarbrick ET; Lobo AJ; Holdsworth CD; Crowe JP; Schofield KJ; Taylor MD
    Aliment Pharmacol Ther; 1998 Dec; 12(12):1207-16. PubMed ID: 9882028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day.
    Giaffer MH; Holdsworth CD; Lennard-Jones JE; Rodrigues CA; McIntyre PB; Manjunatha S; Baron JH; Barrison IG; Polson RJ; Hoare AM
    Aliment Pharmacol Ther; 1992 Aug; 6(4):479-85. PubMed ID: 1358234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months.
    Green JR; Swan CH; Rowlinson A; Gibson JA; Brown P; Kerr GD; Swarbrick ET; Thornton P
    Aliment Pharmacol Ther; 1992 Oct; 6(5):647-52. PubMed ID: 1420754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
    Green JR; Mansfield JC; Gibson JA; Kerr GD; Thornton PC
    Aliment Pharmacol Ther; 2002 Jan; 16(1):61-8. PubMed ID: 11856079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: balsalazide therapy in ulcerative colitis.
    Ragunath K; Williams JG
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1549-54. PubMed ID: 11563993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study.
    Ardizzone S; Petrillo M; Molteni P; Desideri S; Bianchi Porro G
    J Clin Gastroenterol; 1995 Dec; 21(4):287-9. PubMed ID: 8583101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effectiveness and tolerance of 5-aminosalicylic acid in short term treatment of patients with ulcerative colitis at a low or medium phase of activity.
    Bresci G; Carrai M; Venturini G; Gambardella L
    Int J Tissue React; 1990; 12(4):243-6. PubMed ID: 1980911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
    Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
    Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
    Muijsers RB; Goa KL
    Drugs; 2002; 62(11):1689-705. PubMed ID: 12109930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
    Rutgeerts P
    Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis.
    Fleig WE; Laudage G; Sommer H; Wellmann W; Stange EF; Riemann J
    Digestion; 1988; 40(3):173-80. PubMed ID: 2906888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
    Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
    Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balsalazide.
    Prakash A; Spencer CM
    Drugs; 1998 Jul; 56(1):83-9; discussion 90. PubMed ID: 9664201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
    Rachmilewitz D
    BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.